Navigation Links
Bionovo Announces 2011 Highlights and Year-End Financial Results
Date:3/30/2012

trogen-based hormone therapy.
  • The Company successfully completed non-clinical toxicology studies of Menerba in two animal species.  As expected, no serious adverse events or toxicities were observed to date from these studies, which were performed at doses much higher than are being tested in the Phase 3 clinical trial. The drug was well tolerated by the animals.
  • The Company has completed the manufacture of the requisite ten batches for the Phase 3 clinical trial of Menerba, and demonstrated to the FDA excellent consistency and quality.
  • The Company was active in developing and accessing the capital markets for needed funding:
  • On March 12, 2012, the Company entered into a securities purchase agreement with certain investors pursuant to which the Investors purchased an aggregate of 14,231,696 shares of its common stock and warrants to purchase 11,485,844 shares of its common stock.  The exercise price of the warrants is $0.03 per share. The warrants expire on March 30, 2012 and as of March 29, 2012, no warrants were exercised.  
  • On December 30, 2011, the Company entered into a $5 million securities purchase agreement with Socius CG II, Ltd. ("Socius").  On January 6, 2012, the Company presented Socius with a notice to purchase 105 shares of Preferred Stock for $1,050,000.  Upon receipt of the notice, Socius exercised its additional investment right for 4,468,085 common shares for $0.235 per share.  The portion of a warrant representing 35% of the Preferred Stock amount became vested and exercisable and accordingly Socius exercised the vested portion of the warrant for 1,563,830 shares for $0.235 per share.  Socius paid for the shares issued in the form of a secured promissory note.  On February 24, 2012, the Company issued Socius 105 shares of Preferred Stock and immediately thereafter redeemed all 105 shares of the Preferred Stock by offsetting the full redemption price for t
    '/>"/>

  • SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
    2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
    3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
    4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
    5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
    6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
    7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
    8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
    9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
    (Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
    (Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
    Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
    (Date:12/19/2014)... 19, 2014 From November 24, 2014, ... for the year 2014 in its Goa retreat . ... Through the Indian winters, from November to March, Siddhi Yoga ... beach of Arambol, Goa. The Goa training sessions will conclude ... of yoga teacher training, the 10th intake is also a ...
    (Date:12/19/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Gliquidone manufacturers and is a valuable source of guidance ... industry. , Firstly, the report provides a basic overview ... technology. Then, the report explores the international and Chinese ...
    (Date:12/19/2014)... (HealthDay News) -- Being in good shape seems to reduce ... looked at data from more than 57,000 Americans, including more ... between 1991 and 2009. Those in the poorest shape ... blood pressure at the start of the study, compared to ... fitness. Of the more than 8,000 people diagnosed with ...
    (Date:12/19/2014)... Amy Norton HealthDay Reporter ... born to moms who were exposed to high levels of ... of developing autism, a U.S. study suggests. Researchers found ... 1990 and 2002, those exposed to the most air pollution ... who later developed autism. And exposure during the third trimester, ...
    (Date:12/19/2014)... (HealthDay News) -- Prostaglandin analogue eye drops -- a ... risk of vision loss in patients with the eye ... by David Garway-Heath, of the Moorfields Eye Hospital and ... more than 500 people newly diagnosed with open-angle glaucoma ... one of the leading causes of blindness. About ...
    Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
    ... in China is smaller than that of many other countries, ... diabetics// of age between 20 and 79 in 2003. ... in China, while diabetics are mostly aged between 60 to ... Department in Beijing University People's Hospital. ,"Although no ...
    ... the Mecca of Fashion, Paris, have uncovered a mechanism ... natural chemical called opiorphin//, a natural pain alleviator, far ... their experiments, rodents were found to experience pain relief ... with the usual dosage of morphine. The finding which ...
    ... with incriminating evidence that warns non-vegetarians who binge on red ... out that eating more than one and a half servings ... breast cancer and another study that vitamin supplements seem ... diseases except for vitamin C which seems to show some ...
    ... fatty acid known as docosahexaenoic acid (DHA) in their ... dementia and Alzheimer’s disease, according to a study. ... been found to increase the risk of dementia and ... of cases of dementia in the elderly, according to ...
    ... Shelnutt and Yujiang Song from Sandia National Laboratories have ... attaches //to a cell which involves a new process that ... Security Administration laboratory. ,An upcoming issue of the German ... Angewandte Chemie Int. Ed which has currently published the same ...
    ... be just a matter of eating a salad a day. ... Americans will welcome a new study that could keep them ... study, conducted by the UCLA School of Public Health and ... revealed eating salads with salad dressing and raw vegetables is ...
    Cached Medicine News:Health News:Red alert to women against red meat consumption 2Health News:Higher Level of Certain Fatty Acid Associated with Lower Dementia Risk 2Health News:Novel methods to view how a drug attaches to a cell 2Health News:A Salad a Day Keeps the Doctor Away This Winter 2
    ... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
    ... For complete orthopedic trauma procedures. ... system, the orthopedic trauma table top ... for easy patient positioning and provides ... key trauma procedures: hip pinnings; femur, ...
    ... The EXOGEN 2000+ device provides a ... nonunion or the acceleration of fresh ... home for 20 minutes daily, or ... your physician determines your fracture to ...
    ... cannulated interference screws have a ... screw divergence. Screws are available ... lengths. Screws are supplied sterile, ... and 9mm dia. (screws are ...
    Medicine Products: